ADRB1 is also an effective target for pharmacotherapy in cardiovascular diseases, and β-blocking medications are acknowledged as first line agents for ventricular rate control in patients with AF (Chen et al., 2003; McMurray and van Veldhuisen, 2014). The gene discussed is ADRB1; the disease is atrial fibrillation.